BR0208027A - Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo - Google Patents

Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo

Info

Publication number
BR0208027A
BR0208027A BR0208027-3A BR0208027A BR0208027A BR 0208027 A BR0208027 A BR 0208027A BR 0208027 A BR0208027 A BR 0208027A BR 0208027 A BR0208027 A BR 0208027A
Authority
BR
Brazil
Prior art keywords
compound
methyl
processes
phenylarylsulfonamide
active ingredient
Prior art date
Application number
BR0208027-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Atsushi Naganawa
Tetsuji Saitoh
Kaoru Kobayashi
Takayuki Maruyama
Yoshihiko Nakai
Shinsuke Hashimoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BR0208027A publication Critical patent/BR0208027A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
BR0208027-3A 2001-03-12 2002-03-11 Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo BR0208027A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Publications (1)

Publication Number Publication Date
BR0208027A true BR0208027A (pt) 2004-12-28

Family

ID=27346214

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208027-3A BR0208027A (pt) 2001-03-12 2002-03-11 Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo

Country Status (24)

Country Link
US (3) US7235667B2 (enExample)
EP (2) EP1612208B1 (enExample)
JP (3) JP3555620B2 (enExample)
KR (1) KR100886854B1 (enExample)
CN (1) CN1294126C (enExample)
AT (2) ATE522513T1 (enExample)
AU (1) AU2002238855B2 (enExample)
BR (1) BR0208027A (enExample)
CA (1) CA2439604C (enExample)
CZ (1) CZ304035B6 (enExample)
DE (1) DE60220255T2 (enExample)
DK (2) DK1369419T3 (enExample)
ES (1) ES2286230T3 (enExample)
HU (1) HU230056B1 (enExample)
IL (2) IL157701A0 (enExample)
MX (1) MXPA03008134A (enExample)
NO (1) NO329682B1 (enExample)
NZ (1) NZ528120A (enExample)
PL (1) PL218750B1 (enExample)
PT (2) PT1612208E (enExample)
RU (1) RU2299202C2 (enExample)
TW (1) TWI317359B (enExample)
WO (1) WO2002072564A1 (enExample)
ZA (1) ZA200306884B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004022549A1 (ja) * 2002-09-09 2005-12-22 小野薬品工業株式会社 4−メチル−1,3−チアゾール−2−イルスルホニルハライドの製造方法
CN100408570C (zh) * 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
WO2005000356A1 (ja) * 2003-06-27 2005-01-06 Ono Pharmaceutical Co., Ltd. 尿路疾患治療剤
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20080033018A1 (en) * 2004-07-05 2008-02-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agents For Overactive Bladder
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
BRPI0807942A2 (pt) * 2007-02-16 2014-07-01 Ono Pharmaceutical Co Agente terapêutico para distúrbio de excreção urinária
ATE554070T1 (de) * 2007-08-01 2012-05-15 Taisho Pharmaceutical Co Ltd Hemmer der s1p1-bindung
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN102076660B (zh) * 2008-06-23 2014-01-08 安斯泰来制药有限公司 磺胺化合物或其盐
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
CN103209960A (zh) * 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
CN106660063B (zh) * 2014-04-30 2019-06-18 佩纳尔维工业有限公司 用于将液体应用于不同形状的盖子上的可编程同心头
SG11201803867TA (en) * 2015-11-13 2018-06-28 Daewoong Pharmaceutical Co Ltd Sodium channel blocker
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
JPS5748534B2 (enExample) 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000069465A1 (en) * 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
WO2001008674A1 (en) 1999-07-29 2001-02-08 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives and remedies for allodynia
US7335776B2 (en) * 2001-03-14 2008-02-26 Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient

Also Published As

Publication number Publication date
EP1369419A4 (en) 2005-03-16
PT1369419E (pt) 2007-08-16
CZ20032452A3 (cs) 2003-11-12
US7629369B2 (en) 2009-12-08
DE60220255T2 (de) 2008-01-17
TWI317359B (en) 2009-11-21
JP3555620B2 (ja) 2004-08-18
JP3741120B2 (ja) 2006-02-01
RU2299202C2 (ru) 2007-05-20
US20050124672A1 (en) 2005-06-09
WO2002072564A1 (en) 2002-09-19
US7235667B2 (en) 2007-06-26
DK1612208T3 (da) 2011-12-12
ATE362924T1 (de) 2007-06-15
PT1612208E (pt) 2011-10-12
JP2006028193A (ja) 2006-02-02
JP4432051B2 (ja) 2010-03-17
KR20030082978A (ko) 2003-10-23
DE60220255D1 (de) 2007-07-05
CZ304035B6 (cs) 2013-08-28
PL365100A1 (en) 2004-12-27
EP1612208A3 (en) 2006-12-06
NO20034007D0 (no) 2003-09-10
EP1612208B1 (en) 2011-08-31
NO329682B1 (no) 2010-11-29
KR100886854B1 (ko) 2009-03-05
IL157701A (en) 2010-06-30
US8088802B2 (en) 2012-01-03
US20100041708A1 (en) 2010-02-18
US20060030713A1 (en) 2006-02-09
NZ528120A (en) 2006-05-26
AU2002238855B2 (en) 2007-12-06
NO20034007L (no) 2003-11-12
RU2003127677A (ru) 2005-03-27
CN1294126C (zh) 2007-01-10
IL157701A0 (en) 2004-03-28
ZA200306884B (en) 2005-03-30
HU230056B1 (hu) 2015-06-29
DK1369419T3 (da) 2007-09-24
CA2439604A1 (en) 2002-09-19
EP1369419A1 (en) 2003-12-10
JPWO2002072564A1 (ja) 2004-07-02
PL218750B1 (pl) 2015-01-30
HUP0400155A2 (hu) 2004-08-30
ATE522513T1 (de) 2011-09-15
JP2004149545A (ja) 2004-05-27
CN1509278A (zh) 2004-06-30
ES2286230T3 (es) 2007-12-01
EP1369419B1 (en) 2007-05-23
EP1612208A2 (en) 2006-01-04
HUP0400155A3 (en) 2007-05-02
CA2439604C (en) 2012-05-01
MXPA03008134A (es) 2004-03-10

Similar Documents

Publication Publication Date Title
MXPA03008134A (es) Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion.
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
BRPI0409109A (pt) novos compostos
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
BR0214825A (pt) Uréias de 2-aminobenzotiazóis como moduladores de adenosina
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
BRPI0313694B8 (pt) derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
HRP20130406T1 (hr) Medikamenti s aktivnošä†u prema receptoru hm74a
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
NO20065904L (no) Terapeutiske forbindelser
GEP20105082B (en) (biphenyl) carboxylic acids and derivatives thereof
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
IL182694A0 (en) Conjugates with anti-inflammatory activity
DE502005010170D1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
HRP20120344T1 (hr) N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
HRP20100208T8 (hr) Postupak liječenja akutnog rinosinusitisa
MA30797B1 (fr) Nouveaux derives indoliques , leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2009006446A (es) Derivados de espiro-piperidina.
EP1179342A4 (en) IMMEDIATE RELEASE MEDICINAL COMPOSITIONS FOR ORAL ADMINISTRATION

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]